1. Home
  2. ETS vs VTGN Comparison

ETS vs VTGN Comparison

Compare ETS & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ETS

Elite Express Holding Inc.

HOLD

Current Price

$1.61

Market Cap

12.0M

Sector

Industrials

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.24

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETS
VTGN
Founded
2020
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
10.8M
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
ETS
VTGN
Price
$1.61
$0.24
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$0.90
AVG Volume (30 Days)
393.4K
569.7K
Earning Date
04-13-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,665,948.00
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
21.57
N/A
52 Week Low
$0.39
$0.20
52 Week High
$1.55
$5.14

Technical Indicators

Market Signals
Indicator
ETS
VTGN
Relative Strength Index (RSI) 76.21 46.52
Support Level $0.47 $0.23
Resistance Level N/A $0.32
Average True Range (ATR) 0.15 0.01
MACD 0.07 0.00
Stochastic Oscillator 99.83 49.49

Price Performance

Historical Comparison
ETS
VTGN

About ETS Elite Express Holding Inc.

Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: